

ASX Announcement

AdAlta appoints Dr Dallas Hartman as Chief Operating Officer

MELBOURNE Australia, 9th October, 2017: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the appointment of experienced executive, Dr Dallas Hartman to the role of Chief Operating Officer.

Dr Hartman will bring his significant knowledge in preclinical development and manufacturing for scale up to this newly created COO role.

Prior to joining AdAlta, Dr Hartman has held a 20 year career in drug development, and was most recently Vice President of Product Development for NASDAQ-listed Nexvet Biopharma (NASDAQ: NVET), a company focused on developing and commercialising novel biologic therapies for companion animals. Prior to that role, Dr Hartman was Director of Analytical Biochemistry for CSL.

AdAlta's CEO, Sam Cobb said Dr Hartman had extensive experience and would provide a valuable addition to the focused AdAlta team. "Dallas will play a crucial role as we progress our current pre-clinical program through the early stages of regulatory approval and partnering."

Dr Hartman commences in the role of COO on 9th October 2017.

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au